BMS reports third quarter 2026 financial results
The company released Q3 2026 earnings and hosted a conference call with investors to review performance ahead of the fiscal year close.
Latest Bristol Myers Squibb News & Updates
See the latest news and media coverage for BMS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global biopharmaceutical company
bms.com- Headquarters
- Lawrence Township, United States
- Company type
- Public company
- Number of employees
- 38,000+
- Industry
- Pharmaceuticals
Last updated
Latest news about Bristol Myers Squibb (BMS)
In short: Bristol Myers Squibb raised its full-year revenue outlook as third-quarter revenue increased.
Company announcements
BMS reports improved survival for lung cancer drug Iza-Bren in phase 3 trial
Results from the PANKU-Lung01 study show Iza-bren doubles median progression-free survival compared to chemotherapy. The dual-targeting ADC also demonstrated a favorable safety profile and high response rate.
BMS reports Phase 3 ALOFT-IPF trial met primary endpoint for admilparant
Admilparant demonstrated statistically significant improvement in forced vital capacity versus placebo at the 60 mg dose with a favorable safety profile.
BMS reports positive Phase 3 results for RYZ101 therapy
The interim analysis of the ACTION-1 trial showed significant improvements in progression-free survival for GEP-NET patients.
Media coverage
The Big Caveat Behind Bristol Myers' Sales Guidance Boost
Bristol Myers Squibb stock rose Thursday despite a "mixed bag" performance that included a miss from its biggest cancer drug.
Bristol Myers' Cobenfy performance called into question amid overall Q3 revenue beat
Bristol Myers Squibb executives faced sharp questions from an analyst on Thursday regarding the slow commercial launch pace of its highly touted Cobenfy. | BMS...
Bristol Myers Squibb Co. Q3 Income Retreats
Bristol Myers Squibb Co. released a profit for third quarter that Drops, from the same period last year. The company's bottom line totaled $2.162 billion...
Nivolumab Presents Superior Survival Results in Phase 3 Melanoma Trials | AJMC
In a press release based off-of results presented at the Society for Melanoma Research 2014 International Congress in Zurich, Switzerland, BMS announced results from phase...
Never miss news about BMS
Track BMS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
BMS competitors & trending companies
Browse news for competitors to BMS and other trending companies.